Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists.
Brulhart
Laure
L
Nissen
Michael J
MJ
Chevallier
Paola
P
Gabay
Cem
C
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001799:Blood Sedimentation; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D004361:Drug Tolerance; D015796:HLA-B27 Antigen / Q000145:classification / Q000235:genetics; D006801:Humans; D007596:Joints / Q000473:pathology / Q000503:physiopathology; D008297:Male; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy / Q000235:genetics; D016059:Range of Motion, Articular; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014605:Uveitis / Q000150:complications / Q000188:drug therapy / Q000235:genetics
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D015796:HLA-B27 Antigen; D014409:Tumor Necrosis Factor-alpha; C502936:tocilizumab